Gian Life Care Limited has entered into a strategic partnership with M/s. Brahma Hospital (HUF) for hospital lab management services, marking a significant expansion in the Uttarakhand healthcare market. The Board of Directors approved this collaboration during their meeting held on February 23, 2026, with the agreement scheduled to take effect from March 01, 2026.

Partnership Details and Structure

The collaboration focuses on strengthening market position in providing diagnostic and related healthcare services in Roorkee, Uttarakhand. The partnership involves a domestic arrangement with no shareholding exchange between the entities.

Financial Impact and Revenue Projections

The partnership is expected to deliver substantial financial benefits to Gian Life Care Limited. The company anticipates significant revenue enhancement and improved profitability from this strategic alliance.

Strategic Rationale and Market Expansion

The agreement represents a strategic move to expand Gian Life Care's presence in the Uttarakhand healthcare sector. The collaboration will enable the company to:

• Strengthen market position in diagnostic services in Roorkee
• Enhance service delivery capabilities in the region
• Generate additional revenue streams through hospital lab management
• Establish a foothold in the multispecialty healthcare segment

Partnership Structure and Compliance

The transaction does not fall under related party transactions, with no promoter or group company interest in the partner entity. M/s. Brahma Hospital (HUF) operates as a Hindu Undivided Family entity running a multispecialty medical care hospital in Roorkee.

Regulatory Disclosure

Gian Life Care Limited has fulfilled its regulatory obligations by informing the Bombay Stock Exchange about this material development under Regulation 30 of the SEBI Listing Regulations. The company provided comprehensive details as required under Schedule III of the Listing Regulations and SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015.

This partnership represents a strategic expansion opportunity for Gian Life Care Limited, positioning the company for enhanced market presence and improved financial performance in the Uttarakhand healthcare market over the next five years.

Gian Life Care Limited announced its unaudited standalone and consolidated financial results for the quarter ended December 31, 2025, following a board meeting held on February 14, 2026. The healthcare and diagnostics company presented mixed performance indicators alongside significant auditor concerns regarding financial transparency.

Standalone Financial Performance

The company's standalone operations showed positive momentum in Q3FY26 compared to the previous quarter. Revenue from operations reached ₹112.28 lakhs, representing a substantial increase from ₹66.00 lakhs in Q2FY26, though it remained below the ₹158.86 lakhs recorded in Q3FY24.

The company successfully returned to profitability with a net profit of ₹12.03 lakhs in Q3FY26, recovering from a loss of ₹46.58 lakhs in the previous quarter. Basic earnings per share improved to ₹0.12 from negative ₹0.45 in Q2FY26.

Consolidated Results

Consolidated financial results, which include subsidiaries Gian Satguru Pathology LLP and Gian Path Lab (India) Pvt. Ltd., showed similar trends with revenue from operations of ₹112.28 lakhs and net profit of ₹10.13 lakhs for Q3FY26.

Significant Auditor Concerns

MSNT & Associates LLP, the company's auditors, raised critical concerns in their review report regarding the company's financial position. The auditors highlighted that while Gian Life Care reported a cash balance of approximately ₹743.78 lakhs as of the reporting date, significant outstanding obligations remain unpaid:

The auditors expressed inability to conclude on the existence and appropriateness of the cash balance due to insufficient audit evidence and the inability to conduct physical verification. This raises questions about the company's liquidity management and financial transparency.

Nine-Month Performance

For the nine months ended December 31, 2025, the company reported standalone revenue from operations of ₹264.98 lakhs compared to ₹551.76 lakhs in the corresponding period of the previous year. The nine-month net loss stood at ₹29.10 lakhs versus a profit of ₹63.69 lakhs in the previous year.

Corporate Governance

The board meeting was conducted on February 14, 2026, from 4:30 PM to 5:30 PM, where directors approved the quarterly results. The company maintains its paid-up equity share capital at 10,341,524 shares with a face value of ₹10 per share. Managing Director Arun Kumar Gupta (DIN: 01331593) signed off on the financial statements, emphasizing the company's commitment to regulatory compliance despite the auditor concerns.